{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:42:05Z","timestamp":1790484125279,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.ijantimicag.2016.04.022","type":"journal-article","created":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T20:04:07Z","timestamp":1464293047000},"page":"61-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis"],"prefix":"10.1016","volume":"48","author":[{"given":"Emanuele","family":"Durante-Mangoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Andini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Parrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Mattucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusi","family":"Cavezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Senese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Trojaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Caprioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Veronica","family":"Diana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Utili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0010","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.jacc.2012.02.029","article-title":"Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys","volume":"59","author":"Duval","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1471-2334-11-48","article-title":"Increasing incidence and mortality of infective endocarditis: a population-based study through a record-linkage system","volume":"11","author":"Fedeli","year":"2011","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0020","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1001\/archinte.168.19.2095","article-title":"Current features of infective endocarditis in the elderly: results of the international collaboration on endocarditis prospective cohort study","volume":"168","author":"Durante-Mangoni","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0025","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/archinternmed.2008.603","article-title":"Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the international collaboration on endocarditis-prospective cohort study","volume":"169","author":"Murdoch","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0030","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s15010-012-0285-y","article-title":"Epidemiology, characteristics, and outcome of infective endocarditis in Italy: the Italian study on endocarditis","volume":"40","author":"Leone","year":"2012","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0035","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11908-014-0429-6","article-title":"High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it","volume":"16","author":"Smith","year":"2014","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0045","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/AAC.00247-06","article-title":"Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers","volume":"50","author":"Benvenuto","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0050","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1128\/AAC.00350-06","article-title":"Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm","volume":"51","author":"Raad","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0055","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1128\/AAC.01728-08","article-title":"Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm","volume":"53","author":"Stewart","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0060","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1128\/AAC.01307-08","article-title":"Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis","volume":"53","author":"Chambers","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0065","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2013.05.005","article-title":"Daptomycin: the role of high-dose and combination therapy for Gram-positive infections","volume":"42","author":"Gould","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0070","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0075","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1345\/aph.1M085","article-title":"Safety and clinical outcomes when utilizing high-dose (\u22658\u2009mg\/kg) daptomycin therapy","volume":"43","author":"Moise","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0080","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1592\/phco.31.6.527","article-title":"High-dose daptomycin for treatment of complicated Gram-positive infections: a large, multicenter, retrospective study","volume":"31","author":"Kullar","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0085","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/cid\/cir805","article-title":"High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis","volume":"54","author":"Durante-Mangoni","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0090","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1128\/AAC.01563-13","article-title":"High-dose daptomycin therapy for left-sided infective endocarditis. A prospective study from the international collaboration on endocarditis (ICE)","volume":"57","author":"Carugati","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0095","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","article-title":"Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1\u2009mg\/L: a matched cohort study","volume":"56","author":"Murray","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0100","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/jac\/dkt294","article-title":"A multicentre evaluation of the effectiveness and safety of high dose daptomycin for the treatment of infective endocarditis","volume":"68","author":"Kullar","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijantimicag.2015.11.005","article-title":"Towards a definition of daptomycin optimal dose: lessons learned from experimental and clinical data","volume":"47","author":"Senneville","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0110","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0115","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/600039","article-title":"Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program","volume":"49","author":"Figueroa","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0120","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ijantimicag.2010.07.011","article-title":"High-dose daptomycin in documented Staphylococcus aureus infections","volume":"36","author":"Bassetti","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0125","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s10096-011-1500-y","article-title":"Safety analysis of high dose (>6\u2009mg\/kg\/day) daptomycin in patients with concomitant statin therapy","volume":"31","author":"Parra-Ruiz","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0130","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1128\/AAC.00526-13","article-title":"Multicenter study of high-dose daptomycin for treatment of enterococcal infections","volume":"57","author":"Casapao","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0135","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1086\/597031","article-title":"Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic","volume":"48","author":"Cosgrove","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0140","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1086\/313753","article-title":"Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis","volume":"30","author":"Li","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0145","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000142926","article-title":"Definition and classification of acute kidney injury","volume":"109","author":"Kellum","year":"2008","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0150","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3109\/00365548.2013.805427","article-title":"Daptomycin-induced acute eosinophilic pneumonia: analysis of the current data and illustrative case reports","volume":"45","author":"Phillips","year":"2013","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0155","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0160","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0165","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0170","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/jac\/dkr450","article-title":"Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy","volume":"67","author":"Gould","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0175","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/11597460-000000000-00000","article-title":"Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports","volume":"35","author":"Kim","year":"2012","journal-title":"Drug Saf"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0180","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/jac\/dkm258","article-title":"Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S.\u2009aureus (MRSA) blood isolates from 2001\u201305","volume":"60","author":"Steinkraus","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0185","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1086\/606027","article-title":"Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance","volume":"200","author":"Bae","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0190","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/cc7774","article-title":"Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock\u2014does the dose matter?","volume":"13","author":"Pea","year":"2009","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0195","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1128\/AAC.00134-09","article-title":"Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis","volume":"53","author":"LaPlante","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.022_bib0200","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/AAC.01602-07","article-title":"Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916301005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916301005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T14:39:39Z","timestamp":1534430379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857916301005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0924857916301005"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.04.022","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}